Prosecution Insights
Last updated: April 19, 2026

Macrogenics Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18442857 BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOF LU, CHENG 1642 Final Rejection Feb 15, 2024
18320599 TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS BRISTOL, LYNN ANNE 1643 Non-Final OA May 19, 2023
18178783 COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF BUNNER, BRIDGET E 1647 Non-Final OA Mar 06, 2023
18164952 Covalent Diabodies and Uses Thereof DUFFY, BRADLEY 1643 Non-Final OA Feb 06, 2023
17787793 Therapy for the Treatment of Cancer LUNDE, GRACE HENRY 1641 Final Rejection Jun 21, 2022
17570530 Covalent Diabodies and Uses Thereof DUFFY, BRADLEY 1643 Non-Final OA Jan 07, 2022

Managing Macrogenics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month